Overview on advance therapt technology: Chimeric antigen receptor (CAE)T celltherapy

Main Article Content

วิทวัส วิริยะบัญชา


Download data is not yet available.

Article Details

Review Article


1.US Food and drug administration. (30 August 2017). FDA approval brings first gene therapy to the United States: CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia. FDA News release. [Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm]

2.Hartmann, J., Schüßler-Lenz, M., Bondanza, A., & Buchholz, C. J. (2017). Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts. EMBO Molecular Medicine, 9(9), 1183–1197.

3.Amadori, A., Zamarchi, R., Silvestro, G. D., Forza, G., Cavatton, G., Danieli, G. A., Chieco-Bianchi, L. (1995). Genetic control of the CD4/CD8 T-cell ratio in humans. Nature Medicine,1(12), 1279-1283.

4.Pennock, N. D., White, J. T., Cross, E. W., Cheney, E. E., Tamburini, B. A., & Kedl, R. M. (2013). T cell responses: naive to memory and everything in between. AJP: Advances in Physiology Education, 37(4), 273-283.

5.Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2013). Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunological Reviews, 257(1), 107-126.

6.Themeli, M., Rivière, I., & Sadelain, M. (2015). New Cell Sources for T Cell Engineering and Adoptive Immunotherapy. Cell Stem Cell, 16(4), 357-366.

7.Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017). Global Manufacturing of CAR T Cell Therapy. Molecular Therapy - Methods & Clinical Development, 4, 92-101.

8.George, B. (2011). Regulations and guidelines governing stem cell based products: Clinical considerations. Perspectives in Clinical Research, 2(3), 94-99.

9.US National cancer institute. (31 August 2017). CAR T cells: Engineering patients’ immune cells to treat their cancers. [Retrieved from https://www.cancer.gov/about-cancer/treatment/research/car-t-cells]

10.Yang, Y., Jacoby, E., & Fry, T. J. (2015). Challenges and opportunities of allogeneic donor-derived CAR T cells. Current Opinion in Hematology, 22(6), 509-515.

11.Hanna, E., Rémuzat, C., Auquier, P., & Toumi, M. (2016). Advanced therapy medicinal products: current and future perspectives. Journal of Market Access & Health Policy, 4(1), 31036.